Dr Mark Crowther is Associate Professor of Medicine and Program Director of the Adult Hematology Residency Training Program at McMaster University. He is a member of the Canadian Critical Care Trials Group.
Dr. Jeffrey Ginsberg is a leading expert in the diagnosis, prevention and management of venous thromboembolism and has led many of the "practice changing" studies published in this area in the last 20 years. He is the recipient of numerous awards and distinctions, most recently an endowed chair at McMaster University allowing him to pursue further research in venous and arterial thrombosis.
Dr. Holger Schünemann is a leading expert in evidence based practice with a particular interest in the development and widespread dissemination of validated evidence scoring criteria. Dr. Schünemann has played an important role in the evolution of evidence based guidelines currently written by organizations such as the American College of Chest Physicians and the American Thoracic Society.
Dr. Ralph Meyer has recently joined the National Cancer Institute of Canada after a distinguished career at McMaster University. Dr. Meyer is responsible for administering the Clinical Trial Program at the NCIC. The NCIC has led or participated in many national and international studies which guide current best treatment practices for disorders such as Hodgkin's disease, multiple myeloma and other hematologic malignancies.
Dr. Richard Lottenberg is a professor of medicine and past Division Chair of the division of Hematology and Oncology. He is currently the Training Program Director at the University of Florida and is widely regarded as an expert in the evidence based management of sickle cell anemia.

This unique new book uses a series of focussed questions, comprehensive literature evaluations and structured grades of recommendation to provide evidence for the treatment of hematological disorders, both malignant and benign. With contributions from leading international experts who have a real understanding of evidence-based medicine the book provides comprehensive reviews accompanied by clinical commentaries and recommendations on the best treatment regimes to adopt for individual patients.
The book is split into two sections: the first examines the methodology underlying evidence based practice, and the second concentrates on the clinical practice of hematology, providing current "best evidence" to guide practice in a series of well-defined clinical situations.
This clinical reference is an invaluable source of evidence-based information distilled into guidance for clinical practice which will be welcomed by practitioners, trainees and associated health professionals.

About the Contributors.
Preface.
Part I: A Guide to the Evidence.
1. Rating the quality of evidence and making recommendations
2. An overview of systematic reviews
3. Interpreting results of clinical research
4. Finding the evidence
5. Applying EBM in clinical practice
6. Using evidence to guide the diagnosis of disease
Part II
7. Diagnosis of Deep Vein Thrombosis
8. Diagnosis of Pulmonary Embolism
9. Initial Therapy of Deep Vein Thrombosis and Pulmonary Embolism
10. Long-term Anticoagulation in Venous Thromboembolism
11. Thrombolytic Therapy for Deep Vein Thrombosis and Pulmonary Embolism
12. Inferior Vena Cava Interruption
13. Management of Venous Thromboembolism in Pregnancy
14. Pediatric Thrombosis
15. Bridging Anticoagulation in Patients who Require
16. Evidence-based approach to the diagnosis and management of thrombotic thrombocytopenic purpura
17. Diagnosis and Management of Disseminated Intravascular Coagulation
18. Diagnosis and Management of Hereditary Bleeding Disorders
19. Diagnosis and Management of Acquired Bleeding Disorders
20. Diagnosis and Management of Heparin-Induced Thrombocytopenia
21. Management of Antiphospholipid Antibody Syndrome
Part III
22. Clinical Questions in iron overload
23. Aplastic Anemia
24. Acquired Anemias
25. Immune thrombocytopenic purpura
26. Neutropenia
27. Hypereosinophilia
28. Porphyrias
29. Membrane and Enzyme Abnormalities of the Erythrocyte
30. Sickle cell disease
31. Evidence-based treatment of thalassemia major
Part IV
32. Acute Lymphoblastic Leukemia in Adults
33. Acute Myeloblastic Leukemia in Adults
34. Acute Myeloid Leukemia in Adults
35. Current Areas of Controversy in the Treatment of Patients
36. Chronic Lymphocytic Leukemia
37. Chronic Myelocytic Leukemia
38. Burkitt's Lymphoma
39. Primary Central Nervous System Lymphoma
40. Diffuse Large B-cell Lymphoma
41. Follicular Lymphoma
42. Lymphoblastic Lymphoma
43. Mantle Cell Lymphoma
44. Peripheral T-cell Lymphoma
45. Classical Hodgkin Lymphoma
46. Nodular Lymphocyte Predominant Hodgkin Lymphoma
47. Essential Thrombocythemia
48. Management of Patients with Polycythemia Vera
49. Multiple Myeloma
50. Waldenstroms Macroglobulinemia
51. Use of Hematopoietic Growth Factors for Hematologic Malignancies
Index.